(Note: Affinia Therapeutics, Inc. withdrew its IPO plans in an SEC filing dated Dec. 2, 2022. The S-1 was filed on Jan. 4, 2022. No terms were filed, although estimated IPO proceeds were $100 million.) We are a preclinical stage company pioneering a new class of rationally designed gene therapies with potentially curative benefit in […]

We currently intend to focus our efforts on identifying high growth technology and tech-enabled businesses domestically and abroad in the consumer Internet, ecommerce, software, healthcare, transportation / mobility and financial services industries, as well as other industries that are being disrupted by advances in technology and on technology paradigms, including artificial intelligence (“AI”), automation, data […]

We intend to seek a business combination with an India-focused technology firm that will benefit from our sponsors’ extensive global investment experience. We will focus on target companies with a valuation of $1 billion or more. (Incorporated in the Cayman Islands)  Our sponsor and the Cartica Funds, which are providing the capital to our sponsor […]

Our mission is to develop therapies that change the treatment paradigm for amyotrophic lateral sclerosis, or ALS, and a broad range of neurodegenerative diseases by keeping neurons alive. Unlike most other cells in the body that regularly die and are replaced as part of healthy function, mature neurons are normally resistant to cell death and […]

We are a clinical-stage biopharmaceutical company focused on developing our lead clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases. CIN-107 is a highly selective, oral small molecule inhibitor of aldosterone synthase, the enzyme responsible for the synthesis of aldosterone in the adrenal gland. CIN-107 has been designed to use a differentiated mechanism of action, direct […]

We are a microglia-focused company dedicated to improving the lives of patients, caregivers and families affected by rare and common neurodegenerative diseases by pursuing the development of disease-modifying therapeutics to restore the vigilance of microglia. Microglia are the sentinel immune cells of the brain and play a critical role in maintaining central nervous system (CNS) […]

We intend to focus our search on wireless telecommunications companies. Our sponsor is an affiliate of Mach FM, a wireless telecommunications business, led by a management team with a shared vision and passion for delivering disruptive technologies to the end-consumer. Jaymes Winters, our CEO, has over 15 years of experience as a CEO in the […]

We intend to focus on businesses in the education, training and education technology (“EdTech”) industries, specifically in Asia (excluding China). Our amended and restated certificate of incorporation will provide that we shall not undertake our initial business combination with any entity with its principal business operations in China (including Hong Kong and Macau). Our management […]

(Note: Justworks, Inc. withdrew its IPO in an SEC letter dated July 13, 2022. The company had filed to go public (S-1) on Dec. 16, 2021. Justworks postponed its IPO on Jan. 12, 2022, “due to market conditions” – hours ahead of when the IPO was scheduled to price for a debut on Jan. 13. […]

We intend to focus on businesses in the technology metals (“Technology Metals”) and energy transition critical materials (“ETMs”) sectors and the geographic region of the company’s search for a prospective target will not include the People’s Republic of China (“China” or the “PRC”) or the special administrative regions of Hong Kong or Macau, and we […]